Clinical data | |
---|---|
Trade names | Cylert, others |
Other names | Pheniminooxazolidinone; Phenylisohydantoin; Phenylpseudohydantoin; Phenilone; 2-Imino-5-phenyl-4-oxazolidinone; 2-Amino-5-phenyl-1,3-oxazol-4(5H)-one |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | Oral[1][2] |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | ≤50%[2][1] |
Metabolism | Liver[2] |
Metabolites | Various[2] |
Elimination half-life | 7–12 hours[1][2] |
Excretion | Mainly urine[2] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.016.763 |
Chemical and physical data | |
Formula | C9H8N2O2 |
Molar mass | 176.175 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(what is this?) (verify) |
Pemoline, sold under the brand name Cylert among others, is a stimulant medication which has been used in the treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy.[2] It has been discontinued in most countries due to rare but serious problems with liver toxicity.[4][5] The medication was taken by mouth.[2]
Side effects of pemoline include insomnia, decreased appetite, abdominal pain, irritability, and headaches.[1][2] Rarely, the medication can cause serious liver damage, and this can result in liver transplantation or death.[6][7] Pemoline is a psychostimulant and acts as a selective dopamine reuptake inhibitor and releasing agent.[1][8][2][9] Hence, it functions as an indirect agonist of dopamine receptors.[10] Pemoline has little effect on norepinephrine and hence has minimal or no cardiovascular or sympathomimetic effects, in contrast to many other stimulants.[1][8][2]
Pemoline was synthesized in 1913 but was not discovered to be a stimulant until the 1930s and was not used in the treatment of ADHD until 1975.[11][12][1] It was withdrawn due to liver toxicity in many countries between 1997 and 2005, including the United States.[13][7][14] However, it remains available in Japan for the treatment of narcolepsy at lower doses than used for ADHD.[5] Pemoline is a schedule IV controlled substance in the United States due to its relation to other stimulants and a potential for misuse.[15][16] It seems to have less misuse potential than other stimulants.[1]
PatrickMarkowitz1997
was invoked but never defined (see the help page).Cylert-Label
was invoked but never defined (see the help page).pmid9185233
was invoked but never defined (see the help page).Fuller_1978
was invoked but never defined (see the help page).pmid9708845
was invoked but never defined (see the help page).ChemischeBerichte1913
was invoked but never defined (see the help page).ActaAcademiaeAboensis1939
was invoked but never defined (see the help page).pmid18793403
was invoked but never defined (see the help page).pmid18217792
was invoked but never defined (see the help page).INCB
was invoked but never defined (see the help page).CRC2014
was invoked but never defined (see the help page).